Diurnal Group plc is a specialty pharmaceutical company that develops hormone therapeutics for the treatment of chronic endocrine conditions. Based in Cardiff, UK, the company's products aim to address conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal Group's flagship products include Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe, and Chronocort, which has completed Phase III clinical trials for targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline includes Native Oral Testosterone, siRNA oligonucleotide therapy, and T3 modified hormone therapy.